Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8807388 | PMC |
| http://dx.doi.org/10.1038/s41375-021-01386-z | DOI Listing |
Publication Analysis
Top Keywords
brentuximab vedotin-containing
4
vedotin-containing escalated
4
escalated beacopp
4
beacopp variants
4
variants newly
4
newly diagnosed
4
diagnosed advanced-stage
4
advanced-stage classical
4
classical hodgkin
4
hodgkin lymphoma
4
Similar Publications
Loss of or decrease in CD30 expression in four patients with anaplastic large cell lymphoma after brentuximab vedotin-containing therapy.
Virchows Arch
March 2024
Department of Diagnostic Pathology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan.
Article Synopsis
- Brentuximab vedotin (BV) is an antibody drug used to treat anaplastic large cell lymphoma (ALCL) and classic Hodgkin lymphoma (CHL), as well as other CD30-positive lymphomas.
- A study analyzed 12 CHL and 9 ALCL patients after BV therapy, finding that 44% of ALCL patients experienced a loss or decrease of CD30 expression, while all CHL patients maintained consistent CD30 levels.
- Patients with decreased CD30 expression received higher cumulative doses of BV and had lower initial CD30 expression; however, this decrease was not linked to specific subtypes of ALCL.
Brentuximab vedotin-containing escalated BEACOPP variants for newly diagnosed advanced-stage classical Hodgkin lymphoma: follow-up analysis of a randomized phase II study from the German Hodgkin Study Group.
Leukemia
February 2022
First Department of Internal Medicine, University of Cologne, Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf, Cologne, Germany.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!